IBDEI0JG ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9521,0)
 ;;=611.1^^67^663^16
 ;;^UTILITY(U,$J,358.3,9521,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9521,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,9521,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,9521,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,9522,0)
 ;;=704.1^^67^663^17
 ;;^UTILITY(U,$J,358.3,9522,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9522,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,9522,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,9522,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,9523,0)
 ;;=251.2^^67^663^30
 ;;^UTILITY(U,$J,358.3,9523,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9523,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,9523,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,9523,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,9524,0)
 ;;=253.2^^67^663^34
 ;;^UTILITY(U,$J,358.3,9524,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9524,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,9524,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,9524,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,9525,0)
 ;;=733.00^^67^663^43
 ;;^UTILITY(U,$J,358.3,9525,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9525,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,9525,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,9525,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,9526,0)
 ;;=278.00^^67^663^40
 ;;^UTILITY(U,$J,358.3,9526,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9526,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,9526,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,9526,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,9527,0)
 ;;=278.01^^67^663^39
 ;;^UTILITY(U,$J,358.3,9527,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9527,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,9527,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,9527,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,9528,0)
 ;;=250.80^^67^663^10
 ;;^UTILITY(U,$J,358.3,9528,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9528,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,9528,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,9528,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,9529,0)
 ;;=250.00^^67^663^5
 ;;^UTILITY(U,$J,358.3,9529,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9529,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,9529,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,9529,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,9530,0)
 ;;=250.40^^67^663^6
 ;;^UTILITY(U,$J,358.3,9530,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9530,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,9530,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,9530,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,9531,0)
 ;;=250.50^^67^663^9
 ;;^UTILITY(U,$J,358.3,9531,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9531,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,9531,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,9531,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,9532,0)
 ;;=250.60^^67^663^7
 ;;^UTILITY(U,$J,358.3,9532,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9532,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,9532,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,9532,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,9533,0)
 ;;=250.70^^67^663^8
 ;;^UTILITY(U,$J,358.3,9533,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9533,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,9533,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,9533,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,9534,0)
 ;;=250.01^^67^663^4
 ;;^UTILITY(U,$J,358.3,9534,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9534,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,9534,1,5,0)
 ;;=5^DM Type I DM W/O Complications
